Gastrointestinal Drugs Advisory Committee (GIDAC) in joint session with the

Drug Safety and Risk Management Advisory Committee (DSaRM)

 

July 31, 2007

 

  FDA

Disclaimer

 

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Material (pdf)

Errata (pdf)

Addendum (ppt) (htm)

 

 

BIOGEN IDEC, Inc

 

Disclaimer

 

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

TYSABRI (natalizumab), BIOGEN IDEC, Inc.

Briefing Material (pdf)

Addendum (pdf)